{"id":"riltozinameran-12-years-of-age-and-older","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)","action":"Monitor","effect":"Increased riluzole levels"},{"drug":"P-glycoprotein inducers (e.g., rifampin, phenytoin)","action":"Monitor","effect":"Decreased riluzole levels"},{"drug":"CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine)","action":"Monitor","effect":"Increased riluzole levels"},{"drug":"CYP1A2 inducers (e.g., rifampin, phenobarbital)","action":"Monitor","effect":"Decreased riluzole levels"},{"drug":"CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Monitor","effect":"Increased riluzole levels"},{"drug":"CYP3A4 inducers (e.g., rifampin, phenytoin)","action":"Monitor","effect":"Decreased riluzole levels"},{"drug":"Other drugs that may increase the risk of bleeding","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[],"contraindications":["LITFULO is contraindicated in patients with known hypersensitivity to ritlecitinib or any of its excipients [see Warnings and Precautions (5.6)]."],"specialPopulations":{"Pregnancy":"No data are available yet regarding the use of Comirnaty Omicron XBB.1.5 during pregnancy. However, there are limited clinical study data (less than 300 pregnancy outcomes) from the use of Comirnaty in pregnant participants. A large amount of observational data from pregnant women  vaccinated with the initially approved Comirnaty vaccine during the second and third trimester have not shown an increase in adverse pregnancy outcomes. While data on pregnancy outcomes following   ...    seen. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy,  Comirnaty Omicron XBB.1.5 has no or negligible influence on the ability to drive and use machines.   ...    The safety of Comirnaty Omicron XBB.1.5 is inferred from safety data of the prior Comirnaty vaccines.","Geriatric use":"text","Paediatric use":"Paediatric formulations available for infants and children aged 6 months to 4 years. For details, please refer to the Summary of Product Characteristics for other formulations. The safety and efficacy of the vaccine in infants aged less than 6 months have not yet been established.","Renal impairment":"text","Hepatic impairment":"text"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:53:36.056341+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:53:45.241003+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL13829/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:53:20.111627+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:53:46.907630+00:00"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/Q9Y6S7","method":"api_direct","source":"UniProt (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"uniprot","retrievedAt":"2026-04-19T21:53:14.262987+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:53:18.743744+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:53:46.907626+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:53:46.907623+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:53:46.907574+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:53:46.907597+00:00"}},"allNames":"riltozinameran 12 years of age and older","offLabel":[],"timeline":[],"aiSummary":"Riltozinameran 12 Years of age and older, developed by Pfizer, holds a significant market position as one of the company’s key products, though specific revenue figures are not provided. Its competitive advantage lies in the Comirnaty original/Omicron BA.1 formulation, which offers robust protection against BA.1 and some protection against BA.4-5, similar to its sibling Tozinameran. A key risk is the lack of clinical trial data, which may impact regulatory approval and market acceptance. The pipeline outlook includes the development of Famtozinameran, which targets BA.4-5 and offers some protection against BA.1, further diversifying Pfizer’s portfolio.","brandName":"Riltozinameran 12 Years of age and older","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Unknown","modality":"Unknown","drugClass":"Unknown","explanation":"Unfortunately, there is limited information available on the mechanism of action of Riltozinameran. It is a marketed drug for Amyotrophic lateral sclerosis (ALS), but the exact mechanism is not described on Wikipedia. This lack of information makes it difficult to understand how the drug works and its potential benefits and risks.","oneSentence":"Mechanism of action is not specified on Wikipedia.","technicalDetail":"The mechanism of action of Riltozinameran is not specified in available literature. It is a treatment for Amyotrophic lateral sclerosis (ALS), but the exact molecular target and pharmacological class are unknown. Further research is needed to fully understand the drug's mechanism."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL13829","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=riltozinameran-12-years-of-age-and-older","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=riltozinameran-12-years-of-age-and-older","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:33:50.897569+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Tozinameran","company":"Pfizer","advantage":"Comirnaty original/Omicron BA.1 (Pfizer) provides protection against BA.1 and some protection against BA.4-5"},{"name":"Riltozinameran","company":"Pfizer","advantage":"Comirnaty original/Omicron BA.1 (Pfizer) provides protection against BA.1 and some protection against BA.4-5"},{"name":"Famtozinameran","company":"Pfizer","advantage":"Comirnaty original/Omicron BA.4-5 (Pfizer) provides protection against BA.4-5 and some protection against BA.1"}],"genericName":"riltozinameran-12-years-of-age-and-older","indications":{"approved":[{"name":"Amyotrophic lateral sclerosis (ALS)","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Riltozinameran 12 Years of age and older","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL13829","moleculeType":"Small molecule","molecularWeight":"768.84"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/Q9Y6S7","function":"","geneName":"unknown","organism":"Homo sapiens","uniprotId":"Q9Y6S7","proteinName":"MutL C-terminal dimerisation domain-containing protein","sequenceLength":391,"molecularWeight":43818,"subcellularLocation":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL13829"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"_revenueScrapedAt":"2026-04-01 10:46:06.083601+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_revenueClearedDupe":"famtozinameran-12-years-of-age-and-older","participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:33:50.897569+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}